Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Revenue (2018 - 2025)

Historic Revenue for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $2.5 million.

  • BioNexus Gene Lab's Revenue fell 329.05% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 221.55%. This contributed to the annual value of $9.5 million for FY2024, which is 266.26% down from last year.
  • BioNexus Gene Lab's Revenue amounted to $2.5 million in Q3 2025, which was down 329.05% from $2.3 million recorded in Q2 2025.
  • BioNexus Gene Lab's Revenue's 5-year high stood at $3.6 million during Q3 2021, with a 5-year trough of $2.0 million in Q2 2024.
  • Its 5-year average for Revenue is $2.7 million, with a median of $2.6 million in 2023.
  • Its Revenue has fluctuated over the past 5 years, first soared by 18021.08% in 2021, then tumbled by 2798.91% in 2022.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Revenue stood at $3.2 million in 2021, then dropped by 12.5% to $2.8 million in 2022, then fell by 19.95% to $2.3 million in 2023, then grew by 11.03% to $2.5 million in 2024, then grew by 0.79% to $2.5 million in 2025.
  • Its Revenue stands at $2.5 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.1 million for Q1 2025.